IDEXX Labs beats Q3 2026 estimates and lifts FY2026 revenue and EPS guidance
+1 new source since this summary was written
IDEXX Laboratories reported third‑quarter 2026 revenue of $1.21 billion, up 10% year‑over‑year, and GAAP diluted EPS of $4.01, an 18% increase. Adjusted EPS was $3.96, beating the consensus $3.72. The company raised its full‑year 2026 revenue outlook to $4.74‑$4.77 billion and EPS outlook to $14.96‑$15.16 per share, while trimming its operating‑margin outlook.
Why it matters
The raised guidance expands the revenue and earnings targets for investors, potentially supporting a higher valuation for IDXX (the company said the outlook reflects strong CAG Diagnostics growth). Analysts note that the beat and outlook lift could drive further share price appreciation (Investing.com report of a 6.1% pre‑market jump).
Key facts
- 1Q3 2026 revenue was $1.21 billion, a 10% YoY increase. investing.com
- 2GAAP diluted EPS for the quarter was $4.01, up 18% YoY. investing.com
- 3Adjusted EPS for the quarter was $3.96, beating the consensus $3.72 by $0.24. investing.com
- 4Full‑year 2026 revenue guidance was raised to $4.74‑$4.77 billion. investing.com
- 5Full‑year 2026 EPS guidance was raised to $14.96‑$15.16 per share. investing.com
- 6Operating margin for the quarter was 33.1%, up 100 basis points. investing.com
Summary written by AlphAI AI Desk from 20 of 24 sources. Not investment advice. Figures are as stated by the linked sources.